Study: NCT06139211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS015
Description: JS015 will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS015
Description: JS015 will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS015
Description: JS015 will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS015
Description: JS015 will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS015
Description: JS015 will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab will be administered intravenously (IV) on day 1 every 21 day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab will be administered intravenously (IV) on day 1 every 21 day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously (IV) on day 1 every 21 day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously (IV) on day 1 every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabin will be administered orally twice daily from day 1 to 14 every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabin will be administered orally twice daily from day 1 to 14 every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered intravenously (IV) on day 1 every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered intravenously (IV) on day 1 every 21 day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab of 5mg/kg will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or7.5mg/kg on day 1 every 21 day cycle, based on different combined chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Albumin-bound paclitaxel will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.